A abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris

Sergey Yu Martsevich, Natalia Koutishenko, Vladimir I Metelitsa

Abstract

Objective—To examine by Holter electrocardiographic monitoring the effect of abruptly stopping nitrate treatment in patients with stable angina pectoris.

Patients—12 men with confirmed ischaemic heart disease and stable exertional class 3 angina (Canadian). All had episodes of horizontal or down sloping ST segment depression during 24 hour electrocardiographic monitoring. All were nitrate responders.

Design—Each patient was given isosorbide dinitrate (10–30 mg four times a day) and placebo (four times a day) for three days in a randomised crossover trial. There was a washout period of 3–5 days between the two treatment periods. Holter monitoring was performed on the third day of isosorbide dinitrate and placebo administration and on the first day of their withdrawal.

Results—When treatment with isosorbide dinitrate was stopped there was a significant increase in the total number and duration of painless episodes of myocardial ischaemia. During placebo and isosorbide dinitrate administration 8 patients had episodes of painless myocardial ischaemia whereas after isosorbide dinitrate cessation they were recorded in all 12 patients. Episodes of silent myocardial ischaemia at rest appeared in 4 patients after isosorbide dinitrate withdrawal.

Conclusion—Abrupt cessation of short-term continuous nitrate treatment in patients with severe angina may cause a rebound increase in myocardial ischaemia which is predominantly silent.

Keywords: rebound myocardial ischaemia; isosorbide dinitrate

The nitrate withdrawal phenomenon is well known. Sudden discontinuation of prolonged industrial exposure to nitrates can lead to chest pain, myocardial infarction, and even sudden death.12 The clinical significance of this phenomenon is still unclear. Few studies have investigated the risk of abrupt nitrate cessation in a clinical setting.

We have examined, by means of Holter electrocardiographic monitoring, the effect of abruptly stopping nitrates in patients with stable angina.

Patients and methods

PATIENTS

We studied 12 men aged 54–65 years (mean 59) with ischaemic heart disease and class 3 (Canadian) stable exertional angina pectoris who had 3–10 episodes of angina each day. All patients had a positive exercise treadmill test with typical angina attacks and horizontal or downsloping ST segment depression of more than 1 mm 0·08 s after the J point; episodes of ST segment depression of more than 1 mm lasting more than a minute during 24 hour Holter electrocardiographic monitoring; a positive response to isosorbide dinitrate defined as increase in the duration of the exercise treadmill test of ≥ 2 minutes two hours after a single dose (compared with a control exercise test). Table 1 shows the patients’ main clinical characteristics.

STUDY DESIGN

The study was approved by the institutional ethics committee. All patients gave written informed consent. The study protocol is shown in fig 1. All antiangial medications were stopped at least 10 days before the study. During the washout period patients performed several exercise treadmill tests to assess the stability of exercise tolerance and to adjust the single effective dose of isosorbide dinitrate (see above).

The study was randomised, single blind, placebo controlled, and crossover in design. One group of patients (n = 6) started with isosorbide dinitrate (four times a day) for three days, followed by a washout period of 3–5 days, and then received placebo for three days. The other group (n = 6) followed the same

Table 1 Baseline clinical characteristics of patients

<table>
<thead>
<tr>
<th>Case no</th>
<th>Age (yr)</th>
<th>Duration of angina (yr)</th>
<th>Previous myocardial infarction</th>
<th>Coronary angiography</th>
<th>Number of occluded vessels</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>62</td>
<td>26</td>
<td>yes</td>
<td>yes</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>62</td>
<td>5</td>
<td>yes</td>
<td>no</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>5</td>
<td>no</td>
<td>yes</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>54</td>
<td>3</td>
<td>yes</td>
<td>yes</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>56</td>
<td>3</td>
<td>yes</td>
<td>yes</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>60</td>
<td>3</td>
<td>yes</td>
<td>no</td>
<td>—</td>
</tr>
<tr>
<td>7</td>
<td>65</td>
<td>6</td>
<td>yes</td>
<td>yes</td>
<td>—</td>
</tr>
<tr>
<td>8</td>
<td>60</td>
<td>1</td>
<td>yes</td>
<td>no</td>
<td>—</td>
</tr>
<tr>
<td>9</td>
<td>56</td>
<td>4</td>
<td>no</td>
<td>yes</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>55</td>
<td>1</td>
<td>no</td>
<td>yes</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>55</td>
<td>8</td>
<td>yes</td>
<td>yes</td>
<td>2</td>
</tr>
<tr>
<td>12</td>
<td>54</td>
<td>9</td>
<td>yes</td>
<td>yes</td>
<td>3</td>
</tr>
</tbody>
</table>
Figure 1 Study design.

Table 2 Exercise treadmill test duration (seconds) (mean (SE)) during isosorbide dinitrate and placebo administration in 12 patients.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Isosorbide dinitrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise duration to the onset of angina</td>
<td>241 (18)</td>
<td>228 (17)</td>
</tr>
<tr>
<td>Exercise duration to the development of onset of moderate severity</td>
<td>290 (22)</td>
<td>270 (16)</td>
</tr>
<tr>
<td>Exercise duration to ST segment depression = 1.0 mm</td>
<td>235 (19)</td>
<td>213 (17)</td>
</tr>
</tbody>
</table>

*P < 0.05; **P < 0.01 versus placebo.

RESULTS

ISOSORBIDE DINITRATE AND EXERCISE TOLERANCE

Two hours after isosorbide dinitrate administration (at 0900) during continuous treatment there was significant increase (in comparison with placebo) in exercise duration to the onset of angina, to the development of angina of moderate severity, and to ST segment depression = 1 mm. At 4.5 hours after the afternoon dose, however, improvement in exercise tolerance was slight and not statistically significant (table 2).

EPODES OF MYOCARDIAL ISCHAEMIA

During regular isosorbide dinitrate administration there was only a tendency towards reduction in the total number of the episodes of myocardial ischaemia and their duration compared with placebo administration. When isosorbide dinitrate was abruptly stopped the number of episodes of myocardial ishaemia and their duration increased significantly. This increase was evident only for painful episodes of myocardial ischaemia (fig 2, table 3).

Values for maximal ST segment depression during placebo and isosorbide dinitrate administration were substantially higher for painful episodes of myocardial ischaemia than for painless ones (table 4). The magnitude of silent ST segment depression tended to decrease during isosorbide dinitrate administration. Cessation of isosorbide dinitrate caused a significant increase in the magnitude of ST segment depression during silent (but not painful) episodes of myocardial ischaemia.

Schedule but started with placebo. Treatment was stopped abruptly: the last dose was given at 1200 noon.

The single effective dose of isosorbide dinitrate was 10 mg in 10 patients, 20 mg in one patient, and 30 mg in one patient. Owing to the lack of placebo identical to isosorbide dinitrate we were unable to perform the study in a double blind manner.

HOLTER ELECTROCARDIOGRAPHIC MONITORING

Two channel Holter 24 hour electrocardiographic monitoring was performed on the third day of isosorbide dinitrate and placebo administration and on the first day of their withdrawal. We used a model 447 portable Holter monitor (Del Mar Avionics, USA). The leads were bipolar and attached to the sites where maximal ST segment deviations had been obtained during exercise treadmill tests. During electrocardiographic monitoring each patient was asked to follow their regular pattern of daily activity and to note any episodes of angina.

The recordings were analysed blindly by a doctor who was unaware of the sequence of drug/placebo administration. A computer-based scanning system (model 750A Innovator, Del Mar Avionics) was used. An ischaemic event was defined as a ST segment depression of more than 1.0 mm 0-08 s after the J point lasting at least one minute.

EXERCISE TREADMILL TESTS

To prove the efficacy of isosorbide dinitrate during continuous administration two exercise treadmill tests were performed on the second day of each treatment regimen at 0900 (two hours after the morning dose) and at 1630 (4.5 hours after the afternoon dose). The protocol of the exercise treadmill test has been described elsewhere.14

STATISTICAL ANALYSIS

The results are presented as mean (SE). To exclude any carry-over effects the data were compared initially by the analysis of variance. The significance of differences between isosorbide dinitrate and placebo was assessed by Student's paired t test. P values of less than 0.05 were regarded as significant.
Increase in silent ischaemia after nitrate withdrawal

Table 3  Number of episodes of myocardial ischaemia during 24 hour Holter electrocardiographic monitoring in 12 patients (mean (SE))

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Isosorbide dinitrate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Administration</td>
<td>Withdrawal</td>
</tr>
<tr>
<td>All</td>
<td>6·8 (1·1)</td>
<td>7·1 (1·3)</td>
</tr>
<tr>
<td>Painful</td>
<td>4·6 (0·9)</td>
<td>4·3 (0·7)</td>
</tr>
<tr>
<td>Silent</td>
<td>2·2 (0·8)</td>
<td>2·8 (0·9)</td>
</tr>
</tbody>
</table>

* P < 0·05 versus placebo.

Table 4  Maximal ST segment depression values (mm) during 24 hour Holter electrocardiographic monitoring in 12 patients (mean (SE))

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Placebo withdrawal</th>
<th>P</th>
<th>Isosorbide dinitrate</th>
<th>Isosorbide dinitrate withdrawal</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Painful</td>
<td>3·06 (0·56)</td>
<td>3·07 (0·53)</td>
<td>NS</td>
<td>2·92 (0·59)</td>
<td>3·01 (0·49)</td>
<td>NS</td>
</tr>
<tr>
<td>EMI</td>
<td>1·68 (0·47)</td>
<td>1·64 (0·45)</td>
<td>NS</td>
<td>1·33 (0·35)</td>
<td>2·16 (0·29)</td>
<td>&lt; 0·05</td>
</tr>
</tbody>
</table>

EMI, episodes of myocardial ischaemia.

INDIVIDUAL RESPONSES

There were silent episodes of myocardial ischaemia during placebo administration in nine of the 12 patients. During continuous isosorbide dinitrate administration silent episodes of myocardial ischaemia persisted in seven patients. After cessation of isosorbide dinitrate all 12 patients had silent episodes of myocardial ischaemia.

Silent myocardial ischaemia at rest was not registered in any patient during placebo administration, after its withdrawal, or during isosorbide dinitrate administration. However, after isosorbide dinitrate cessation episodes of silent myocardial ischaemia at rest were found in four patients.

Discussion

The results of the present study show that abrupt discontinuation of short-term continuous isosorbide dinitrate treatment in patients with severe stable angina pectoris can exacerbate myocardial ischaemia. The rebound effect after nitrate cessation was first described in people who had been exposed to high doses of nitrates in the munitions industry.13 Although clinical data on the possibility of nitrate rebound are scarce,15 some studies report evidence of signs of a nitrate rebound phenomenon in clinical setting.

Thus, Georgopoulos et al found an increase in the number of anginal attacks with a corresponding increase in consumption of glyceryl trinitrate in several patients during the first two days after completion of the 14 days of continuous transdermal glyceryl trinitrate treatment.14 In our previous study we detected a tendency towards an increase in exercise induced ST segment depression an hour after the removal of a single dose of transdermal glyceryl trinitrate.8 Rehnqvist et al described the appearance of severe angina necessitating admission to hospital in three of 32 patients after abrupt withdrawal of controlled-release isosorbide-5-mononitrate, although they were not sure that this was true rebound phenomenon and not simply the result of the withdrawal of beneficial treatment.8

The possibility of a nitrate withdrawal phe-
drawal. This fact may partially explain the discrepancies between the results of our study and the studies that have not found clinically relevant rebound.

There is another explanation for the size of the rebound after nitrate withdrawal that was found in the present study. Most patients included in the studies which did not find any signs of nitrate withdrawal phenomenon had moderately severe angina and/or were being treated with concomitant antianginal agents (β adrenoblockers or calcium antagonists). This was not the case in our study where all patients had class 3 angina, lower exercise tolerance, and frequent episodes of angina; no patient received any additional antianginal treatment during the study. It can be concluded, therefore, that the withdrawal phenomenon is far more likely to occur in patients with advanced ischaemic heart disease and severe angina pectoris: it may not be a problem in patients with less severe angina.

There could be a relation between the rebound phenomenon and the development of tolerance to nitrates, although this is not yet established. We can speculate that because the effect of isosorbide dinitrate on ischaemic episodes was slight tolerance to nitrates had developed in our patients. However, exercise tests showed a significant increase in exercise duration two hours after drug administration so perhaps tolerance was only partial.

It is arguable whether these relatively minor changes in ischaemic profile after the end of nitrate treatment are of any clinical significance. However, many believe that silent myocardial ischaemia is an important influence on prognosis and that treatment should aim at eliminating or decreasing painless ischaemic episodes as well as painful ones.

CLINICAL IMPLICATIONS

Nitrates are abruptly stopped in different situations—for example, during physician-initiated drug withdrawal because tolerance or side effects have developed or when a patient does not comply with the treatment regimen. It may also occur when nitrates are prescribed intermittently. The results of our study suggest that the dose should be tapered if continuous treatment with nitrates has to be stopped. We recommend that cautious attention is paid to all forms of intermittent nitrate treatment in patients with severe angina pectoris.

Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris.

S. Y. Martsevich, N. Koutishenko and V. I. Metelitsa

*Heart* 1996 75: 447-450
doi: 10.1136/hrt.75.5.447

Updated information and services can be found at:
[http://heart.bmj.com/content/75/5/447](http://heart.bmj.com/content/75/5/447)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)